GLP-1 Agonist in the Treatment of Parkinson, New Innovations: A Literature Review

Imadeddin Mohamad Barakat *

Specialist Internal Medicine, Danat Al Emarat Hospital, United Arab Emirates.

*Author to whom correspondence should be addressed.


Parkinson’s disease (PD) is a progressive neurodegenerative condition marked by the gradual deterioration of dopaminergic neurons, leading to severe motor and non-motor symptoms. Conventional treatments primarily focus on symptom management rather than addressing the underlying disease progression. However, recent scientific investigations have illuminated the potential of GLP-1 agonists in offering neuroprotection and enhancing motor function among individuals with PD. Originally designed to tackle type 2 diabetes, GLP-1 (glucagon-like peptide-1) agonists have attracted considerable interest due to their multifaceted impacts extending beyond glycemic regulation. In the realm of PD, preclinical trials have unveiled the neuroprotective attributes of GLP-1 agonists, which include anti-inflammatory, anti-apoptotic, and neurotrophic properties. These mechanisms present a promising avenue for therapeutic intervention aimed at slowing down or even arresting the progression of PD. Numerous clinical studies have explored the efficacy of GLP-1 agonists in PD patients, yielding promising outcomes. Exenatide, a commonly studied GLP-1 agonist, has shown improvements in motor symptoms, as well as potential disease-modifying effects. Other GLP-1 agonists, such as Liraglutide and Dulaglutide, have also exhibited promising results in small-scale trials. However, challenges such as optimal dosing, long-term safety, and patient selection remain to be addressed. Continued research efforts are warranted to refine GLP-1 agonist therapy and pave the way for improved outcomes in PD management. This article aims to review all the aspects related to Parkinson’s disease and the usage of GLP-1 agonists in the affected patients. It shall reflect upon all the relevant information that is required for a physician to know before diagnosing such conditions and prescribing the appropriate medications for the patients.

Keywords: Parkinson’s disease, GLP-1 agonists, treatment therapy, new interventions, successful outcome

How to Cite

Barakat, Imadeddin Mohamad. 2024. “GLP-1 Agonist in the Treatment of Parkinson, New Innovations: A Literature Review”. Asian Journal of Research and Reports in Neurology 7 (1):42-47.


Download data is not yet available.


Zafar S, Yaddanapudi SS. Parkinson Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available: [Accessed on: 2024 Feb 14].

Kouli A, Torsney KM, Kuan WL. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Available: [Accessed on: 2024 Feb 15].

DeMaagd G, Philip A. Parkinson’s disease and its management. Pharm Ther. 2015;40 (8):504–32.

Shrimanker I, Tadi P, Sánchez-Manso JC. Parkinsonism. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Available: [Accessed on: 2024 Feb 15].

Emamzadeh FN, Surguchov A. Parkinson’s disease: Biomarkers, treatment, and risk factors. Front Neurosci. 2018;12:612.

Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. CMAJ Can Med Assoc J. 2016;188(16):1157–65.

Armstrong MJ, Okun MS. Diagnosis and treatment of parkinson disease: A Review. JAMA. 2020;323(6):548–60.

Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s Disease: Current Status and Future Developments. Curr Neuropharmacol. 2018;16(8):1239–52.

Zahoor I, Shafi A, Haq E. Pharmacological Treatment of Parkinson’s Disease. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018. Available: [Accessed on: 2024 Feb 15].

Moore JJ, Saadabadi A. Selegiline. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Available: [cited 2024 Feb 15].

Lampropoulos IC, Malli F, Sinani O, Gourgoulianis KI, Xiromerisiou G. Worldwide trends in mortality related to Parkinson’s disease in the period of 1994–2019: Analysis of vital registration data from the WHO Mortality Database. Front Neurol. 2022;13:956440.

Ryu DW, Han K, Cho AH. Mortality and causes of death in patients with Parkinson’s disease: a nationwide population-based cohort study. Front Neurol. 2023;14:1236296.

Chen F, Chen S, Si A, Luo Y, Hu W, Zhang Y, et al. The long-term trend of Parkinson’s disease incidence and mortality in China and a Bayesian projection from 2020 to 2030. Front Aging Neurosci. 2022;14:973310.

Macleod AD, Taylor KSM, Counsell CE. Mortality in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord Off J Mov Disord Soc. 2014;29 (13):1615–22.

Vaccari C, Grotto D, Pereira T da V, de Camargo JLV, Lopes LC. GLP-1 and GIP receptor agonists in the treatment of Parkinson’s disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies. PLoS ONE. 2021;16(8):e0255726.

Mulvaney CA, Duarte GS, Handley J, Evans DJ, Menon S, Wyse R, et al. GLP-1 receptor agonists for Parkinson’s disease. Cochrane Database Syst Rev. 2020;7(7):CD012990.

Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available: [Accessed on: 2024 Feb 15].

Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12:204201882 1997320.

Glotfelty EJ, Olson L, Karlsson TE, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease. Expert Opin Investig Drugs. 2020;29(6):595–602.

Bayram E, Litvan I. Lowering the risk of Parkinson’s disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes. Brain. 2020;143(10):2868–71.

McFarthing K, Larson D, Simuni T. Clinical Trial Highlights – GLP-1 agonists. J Park Dis. 10(2):355–68.

Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, et al. Linked clinical trials--the development of new clinical learning studies in Parkinson’s disease using screening of multiple prospective new treatments. J Park Dis. 2013;3(3):231–9.

Svenningsson P, Wirdefeldt K, Yin L, Fang F, Markaki I, Efendic S, et al. Reduced incidence of Parkinson’s disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. Mov Disord Off J Mov Disord Soc. 2016;31(9):1422–3.

Lin YH, Hsu CC, Liu JS, Chang KC, Huang JA. Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson’s disease in diabetic patients. Sci Rep. 2023;13:22489.

Nemade D, Subramanian T, Shivkumar V. An update on medical and surgical treatments of Parkinson’s Disease. Aging Dis. 2021;12(4):1021–35.

Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest. 2013;123(6):2730–6.

Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2017; 390(10103):1664–75.

Athauda D, Wyse R, Brundin P, Foltynie T. Is Exenatide a Treatment for Parkinson’s Disease? J Park Dis. 2017;7(3):451–8.

Vijiaratnam N, Girges C, Auld G, Chau M, Maclagan K, King A, et al. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study. BMJ Open. 2021; 11(5):e047993.

Athauda D, Maclagan K, Budnik N, Zampedri L, Hibbert S, Skene SS, et al. What effects might exenatide have on non-motor symptoms in Parkinson’s Disease: A Post Hoc Analysis. J Park Dis. 2018;8(2):247–58.